“…Sickle cell anemia is now recognized as a global health problem (Kato et al, 2018) and while curative therapy for SCA exists in the form of hematopoietic stem cell transplantation, its availability is very restricted (Yawn et al, 2014). Despite concerted efforts by researchers and the pharmaceutical industry to develop novel drugs for the treatment of SCA (Telen, 2016;Conran and Torres, 2019), only three substances have been FDA approved for SCA therapy since hydroxyurea's approval over 20 years ago, and it is probable that multi-drug approaches, possibly still involving the use of hydroxyurea, will evolve for the management of the disease (Carden and Little, 2019).…”